Participated · Series A · Mar 2023

Genialis develops ResponderID, a machine-learning-driven platform that generates predictive biomarkers and molecular portraits from NGS-based data to inform clinical and translational research. The company partners with biopharma to analyze clinical-trial data, inform trial design, and supports commercialization of next‑gen biomarker assays with diagnostic firms. Genialis reports multiple scientific outputs, including ten publications/posters and a co‑authored Journal of Clinical Oncology paper using its models. The company plans to expand its proprietary ResponderID platform and build a comprehensive collection of clinically validated biomarker models to provide pinpoint diagnoses for cancer patients. Genialis is growing teams in both the U.S. and Slovenia and investing in R&D collaborations with cancer centers, hospital groups, and academic labs. Financially, the company announced a Series A round of more than $13 million to fund these product and commercial expansions. Genialis provides SaaS-based biological visual analytics software and an application for variant discovery by targeted genome sequencing. Its system aims to learn how users prefer to interact with their data and to optimize analysis and the user experience based on user-generated content and public data. Early access users on the Expressions and variant discovery apps include researchers from Harvard University, CPMCRI, Johns Hopkins and Jackson Labs. The company is based in Houston, Texas; Cambridge, Massachusetts; and Ljubljana, Slovenia. Genialis recently closed a $2.3M seed funding round. It intends to use the funds to accelerate the team’s expansion in the U.S. and to commercialize its platform.

Participated · Series B · Nov 2021

Clarapath develops robotics, machine vision and digital automation tools to modernize how pathology laboratories process tissue, with its SectionStar system positioned as an all‑in‑one tissue sectioning and transfer solution. SectionStar is described as the first (pending U.S. launch) system that increases capacity, reliability and consistency while reducing the need for highly skilled labor. The company says its automation captures and aggregates new data to improve downstream digital pathology and diagnostic review. Clarapath cites a strained laboratory environment driven by severe labor shortages, rising caseloads and antiquated manual workflows as rationale for its products; the article notes more than 12 million human and veterinary biopsies are performed annually in the U.S. The company operates medical device development in Hawthorne, NY and runs a CLIA‑certified laboratory serving clinical and non‑clinical organizations. With this financing, Clarapath plans to accelerate commercialization of SectionStar and expand sales, service, precision manufacturing and R&D to build an end‑to‑end 'lab of the future.' Clarapath develops SectionStar, a fully automated, all‑in‑one tissue sectioning and transfer system that standardizes and accelerates the preparation of glass slides for pathology. SectionStar consolidates manual cutting, quality control, and decision steps to produce more consistent tissue sections and support AI‑driven analysis. The company says the system increases throughput, reduces reliance on skilled labor, and generates richer datasets for molecular mapping and precision‑medicine research. Clarapath works with research and clinical customers today, including Northwell Health and The Ellison Institute, and operates a CLIA‑certified clinical research organization that offers whole slide imaging and automated image processing. The company plans to launch SectionStar first in the non‑clinical market in the near term while targeting the larger clinical market as its ultimate goal. Recent financing will support product development, team growth, and expanded sales and service efforts.

Participated · Series A · Jun 2021

Figur8 develops the bioMotion Assessment Platform (bMAP) to produce objective data for musculoskeletal (MSK) care and injury recovery. The company positions itself as a market leader for standardizing MSK health and injury recovery data. bMAP empowers individuals to monitor and optimize injury recovery and physical performance, while enabling providers, patients and payers to access data for advanced insights and more personalized care. The platform's objective measurements help providers communicate symptoms, diagnosis and progress, and help payers improve claims, underwriting and risk management. Figur8 intends to use the recent funding to drive growth and adoption of bMAP. The company is led by founder and CEO Nan‑Wei Gong and is based in Boston, MA. FIGUR8 has developed a wearable musculoskeletal diagnostics system that captures over one million unique data points from a single movement to pinpoint the source and severity of soft-tissue injuries and provide real-time recovery visibility. The company’s solution delivers quantitative MSK assessments in minutes by users of varying clinical expertise and is positioned as a screening alternative to MRIs and X-rays for soft-tissue symptoms. Technology was developed over years by MIT engineers in collaboration with Mass General Brigham clinicians. FIGUR8 recently expanded product offerings to target the low back, neck, lumbar spine and knee. Management says the product is intended for deployment with major health systems, government organizations and large employers. The company emphasizes adoption across clinical and non-athletic settings, citing interest from clinicians and users including professional athletes. Financially, FIGUR8 announced a new financing to support these deployments and product expansion. Figur8 is a diagnostics platform that captures three-dimensional skeletal movement and muscle output to provide objective measures of musculoskeletal performance and recovery. Its portable system, developed with MGH Sports Science Lab and MIT Media Lab researchers, enables clinicians to assess cause, effect and quality of movement. The platform quantifies micrometer-precision signals of muscle activity and joint mobility to produce over one million unique data points from a single movement assessment, which are analyzed by algorithms to generate actionable biomechanical insights. In minutes clinicians can establish movement-health baselines, diagnose dysfunction, identify injury risk, optimize exercise routines and monitor progress. The company is working with elite athletes, teams, training facilities and major occupational and physical therapy clinics. Figur8 is led by CEO Dr. Nan-Wei Gong and recently closed seed funding to support its work.

Participated · Series A · Jun 2021

Hawthorne Effect operates a tech-driven platform, the Hawthorne Cloud, that decentralizes clinical trials and pairs assessments with a network of trained medical professionals called Hawthorne Heroes. Its service model delivers complete assessments whenever, wherever and however trials and patients require, and the company can run trials as a single virtual site. Since launching in 2015, the solution has been used across more than 50 clinical trials and the company is actively engaged with more than 260 clinical sites. Led by founder and CEO Jodi Akin, Hawthorne Effect aims to alleviate key issues related to patient recruitment and retention. The company raised $20M in a Series A and intends to use the funds to accelerate growth and scale operations. It is based in San Francisco, CA.

Participated · Series B · Jan 2021

Conversa Health provides an enterprise virtual care and communication platform that links providers’ EHRs and patient data to interactive digital care pathways and a clinical analytics engine to automate care management 24×7. Its platform and library of digital pathways are used by providers to manage patients across populations rather than one-off point solutions, improving pre- and post-visit care-plan adherence. During the COVID-19 pandemic the company’s customer count grew fourfold and its financial metrics increased sixfold as larger customers expanded use of the platform. Conversa is expanding its product to support vaccination programs for consumer education and post-vaccination monitoring. To capitalize on recent momentum the company plans to hire more engineers and scale the platform. Company leadership believes remote and automated care will remain in demand after the pandemic and anticipates significant growth in virtual care delivery. Conversa Health offers an automated, chat-based virtual care and communication platform that triages patients, gathers patient data, and integrates with connected devices. The company positions its platform as the digital front door for health systems, aiming to scale personalized engagement and care. Conversa has launched Employee HealthCheck to screen workers before they return to work and has additional programs to screen for mental health concerns. The platform is being used by providers to check patients and loved ones before facility visits and to manage COVID-related workflows. Northwell Health has used Conversa to scale communications and care for thousands of COVID-19 patients with programs focused on lab results, quarantine and antibody tests. The company characterizes itself as, in many ways, a data company. Conversa is a San Francisco-based healthcare conversation platform that aims to improve doctor–patient communication. Its Conversa Conversation Platform™ delivers smart, automated, patient-profile driven conversations across key health experiences including chronic condition management, post-discharge and pre- and post-surgery care, patient education, medication adherence, appointment scheduling and lifestyle coaching. The platform sources data from more than 400 biometric devices together with clinical, claims and patient-generated data to provide providers with real-time information for care adjustments and resource allocation. Conversa is being adopted by health systems such as Northwell, Ochsner Health System, Citrus Valley Health Partners and Centura Health’s Penrose St. Francis. Led by CEO and co-founder West Shell III, the company plans to use its newly raised capital to expand product capabilities, grow its clinical conversation library, enhance customer and distribution partner operations, and scale the team. Financially, Conversa secured $8M in Series A funding led by Northwell Ventures with participation from Epic Ventures, Healthgrades and existing investors. Conversa Health is a San Francisco, CA–based provider of patient relationship management services. Led by co-founder and CEO West Shell III and newly named CTO Daniel Dean, the company offers its Digital Checkup™ platform. The Digital Checkup™ automates delivery of personalized messaging based on a longitudinal patient profile dynamically derived from EHRs, biometric devices and self-reported data. Conversa aims to enhance the physician–patient relationship through continuous, collaborative, structured communications between visits. The company closed a $2.5M seed funding round and intends to use the proceeds to expand its Digital Checkup service with distribution partners in care management, population health and customer relationship management.